Sorafenib with or without concurrent transarterial chemoembolization in patients with advanced hepatocellular carcinoma: a phase III STAH trial

Primary liver cancer, including hepatocellular carcinoma (HCC), is the fifth and second commonest cancer and cause of cancer-related mortality, respectively, worldwide.[1] HCC prognosis remains poor owing to underlying chronic liver disease, late diagnosis, and frequent recurrence-progression after treatment; many patients with HCC are diagnosed at advanced stages.[2,3]
Source: Journal of Hepatology - Category: Gastroenterology Authors: Source Type: research